Tower Research Capital (TRC)’s Boundless Bio BOLD Stock Holding History

Tower Research Capital (TRC)’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$870	Sell	348 -2,023	-85%	-$3.12K	﹤0.01%	4925
2026 Q1	$2.61K	Sell	2,371 -3,432	-59%	-$4.01K	﹤0.01%	4445
2025 Q4	$6.96K	Buy	5,803 +3,210	+124%	+$4K	﹤0.01%	4039
2025 Q3	$3.19K	Sell	2,593 -3,479	-57%	-$4.01K	﹤0.01%	4536
2025 Q2	$6.13K	Sell	6,072 -346	-5%	-$460	﹤0.01%	4129
2025 Q1	$9.69K	Buy	6,418 +2,323	+57%	+$4.82K	﹤0.01%	3743
2024 Q4	$11.9K	Buy	4,095 +1,190	+41%	+$3.47K	﹤0.01%	3672
2024 Q3	$10.1K	Sell	2,905 -368	-11%	-$1.33K	﹤0.01%	3800
2024 Q2	$12.7K	Buy	+3,273	New	+$31.3K	﹤0.01%	4020

Other funds holding BOLD

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Tower Research Capital (TRC)'s BOLD Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Boundless Bio (BOLD) stake by 85% in Q2 2026, selling an estimated $3.12K and leaving 348 shares worth $870. The position accounts for ﹤0.01% of the portfolio, ranked #4925.

Tower Research Capital (TRC) first reported a position in BOLD in Q2 2024 and has held it in 9 quarters since. The position peaked at $12.7K in Q2 2024. 40 funds tracked by Wall St. Rank hold BOLD as of Q2 2026.

Tower Research Capital (TRC) held 348 shares of Boundless Bio worth $870 as of Q2 2026.
Tower Research Capital (TRC) sold 2,023 Boundless Bio shares in Q2 2026, an estimated $3.12K.
Boundless Bio made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4925 holding.
Tower Research Capital (TRC) first reported a position in Boundless Bio in Q2 2024 and has held it in 9 quarters since.
Tower Research Capital (TRC)'s Boundless Bio position peaked at $12.7K in Q2 2024.
40 funds tracked by Wall St. Rank held Boundless Bio as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.